Study: Stereotactic body radiotherapy can be safely used to treat patients with multiple metastases
The first National Institutes of Health (NIH) National Cancer Institute (NCI)-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases. These results were recently published in
JAMA Oncology.
The results of the Phase I NRG-BR001 trial, conducted by the NCI National Clinical Trials Network group NRG Oncology, indicate that SBRT treatment in standard doses was safe for 35 evaluable patients with a median of 3 metastases. There were no dose-limiting toxicities and over 50% of trial participants were alive at 2 years following treatment.
E-Mail
PHILADELPHIA, PA - The first National Institutes of Health (NIH) National Cancer Institute (NCI)-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases. These results were recently published in
JAMA Oncology.
The results of the Phase I NRG-BR001 trial, conducted by the NCI National Clinical Trials Network group NRG Oncology, indicate that SBRT treatment in standard doses was safe for 35 evaluable patients with a median of 3 metastases. There were no dose-limiting toxicities and over 50% of trial participants were alive at 2 years following treatment.
James H. Doroshow, M.D.
Director, Division of Cancer Treatment and Diagnosis
As the National Cancer Institute (NCI) Deputy Director for Clinical and Translational Research, Dr. James H. Doroshow works closely with the NCI director and other deputy directors to carry out NCI’s mission, particularly as it relates to clinical trials and translational investigations.
In early 2020, as part of NCI’s response to the COVID-19 pandemic, Dr. Doroshow led the rapid launch of the NCI COVID-19 in Cancer Patients Study (NCCAPS). In this natural history study, researchers will follow 2,000 individuals with cancer and COVID-19 and collect clinical information and biospecimens over two years. Findings will inform our understanding of COVID-19’s impact on patients with cancer, as well as cancer’s impact on the course of COVID-19, and how both can best be managed.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
April 10, 2021 GMT
BOULDER, Colo. (BUSINESS WIRE) Apr 10, 2021
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (RUCA-J) will be presented during week one of the American Association for Cancer Research Virtual Annual Meeting (AACR), taking place April 10-15, 2021.
“We remain committed to understanding how Rubraca may benefit patients with cancer, and the data presented at AACR further enhance our understanding in different patient populations and solid tumor types,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “The Phase 1b RAMP data for the combination of Rubra
Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.